Studies regarding the functions of the bovine papillomavirus (BPV) E5 oncoprotein in vivo are lacking and no E5-mediated mechanism underlying epithelial carcinogenesis is known. We have shown that BPV-2 DNA is present in the majority of naturally occurring urinary bladder tumours of cattle and that E5 is expressed in the cancer cells. Here we show that the interaction between the platelet-derived growth factor (PDGF) b receptor and BPV E5, described in vitro in cultured cells, takes place in vivo in bovine urinary bladder cancers. In these cancers, E5 and PDGF b receptor colocalize, as shown by confocal microscopy, and physically interact, as shown by coimmunoprecipitation. Furthermore, the PDGF b receptor associated with E5 is highly phosphorylated, suggesting the functional activation of the receptor upon E5 interaction. Our results demonstrate, for the first time, that E5-PDGF b receptor interaction occurs during the natural history of bovine urinary bladder tumours, suggesting an important role for E5 in carcinogenesis. Finally, the system provides a suitable animal model of papillomavirus-associated cancer to test therapeutic vaccination against E5. Successful bladder tumour regression would provide a valuable model for therapeutic vaccination against papillomavirus-associated tumours.
Introduction
Urinary bladder tumours are known to occur rarely in animals. However, cattle grazing on bracken ferninfested lands and suffering from chronic enzootic haematuria (CEH) frequently develop bladder cancer involving both the epithelium and mesenchyme (Pamukcu et al., 1976) .
CEH is a severe syndrome due to prolonged ingestion of bracken fern (Pteridium spp), the only plant proven to cause cancer in animals . This syndrome occurs in several areas worldwide and is very common in Southern Italy, where bracken is widespread (Borzacchiello et al., 2003b) .
It was first suggested in the 1960s that a papillomavirus is associated with bladder cancer in cattle (Olson et al., 1965) , and since then Campo and co-workers established a strong relationship between bovine papillomavirus (BPV)-2 and bracken fern in both experimental and naturally occurring bovine bladder cancer (Campo et al., 1992) . Although the synergism between the virus and bracken is still poorly understood, it is likely that BPV-2 infects the bladder mucosa, producing an abortive latent infection, as no structural proteins or virions are found in the urinary bladder mucosa (Campo et al., 1992; Borzacchiello et al., 2003c) . Immunosuppressants and chemical carcinogens from bracken act synergistically with the viral proteins, inducing neoplastic disease, and it has been suggested that latent BPV is activated by bracken-induced immunosuppression, thus initiating progression to malignancy (Campo, 1997) . BPV-2 DNA has also been detected in lymphocytes from field cases of cattle, both healthy and suffering from CEH and urinary bladder cancer (S Roperto, unpublished observation; Campo et al., 1994; Stocco dos Santos et al., 1998) , suggesting that the peripheral blood cells can function as a reservoir for latent virus. It has been proposed that papillomavirus is involved also in human urinary bladder cancers (Shibutani et al., 1992; Agliano et al., 1994; De Gaetani et al., 1999) , but this suggestion is often not corroborated (Oliver et al., 1998) .
The papillomavirus E5 proteins are short hydrophobic polypeptides (from 83 amino-acid residues in human papillomavirus type 16 (HPV-16) to 42 residues in BPV-4), many of which have transforming activity. E5 is the major oncoprotein of BPV; it is expressed in the deep layers of the epithelium (Burnett et al., 1992; Anderson et al., 1997; Venuti and Campo, 2002) and is localized largely to the membranes of the endoplasmic reticulum (ER) and Golgi apparatus (GA) of the host cells (Burkhardt et al., 1989; Pennie et al., 1993) .
Owing to its relatively small size and structure, it is unlikely that E5 induces transformation by an enzymatic function. E5 is thought to induce cell transformation in vitro through the activation of several kinases, from growth factor receptors to cdk cyclins (Venuti and Campo, 2002) . E5 interacts with the 16-K subunit c protein, a component of the vacuolar H þ -ATPase pump Goldstein et al., 1991; Conrad et al., 1993; Faccini et al., 1996) . The pump is critical for the function of cellular compartments that process growth factors and binding of the E5 protein may result in alteration of this processing.
Additionally, many studies have shown that the BPV-1 E5 protein transforms cells by binding to and activating the cellular b receptor for the platelet-derived growth factor (PDGF b) (Petti et al., 1991 (Petti et al., , 1997 Petti and DiMaio, 1992; DiMaio et al., 2000; DiMaio and Mattoon, 2001) . Evidence suggests that receptor activation by the E5 protein is induced upon its dimerization (Lai et al., 1998) . Constitutive activation of the receptor tyrosine kinase is a key event mediating the transforming effects of E5 in vitro (Nilson and DiMaio, 1993; Drummond-Barbosa et al., 1995) .
The interaction of E5 and the PDGF b receptor has not been investigated in vivo and data about the mechanisms underlying E5 oncogenic transformation in vivo are lacking. Leptak et al. (1991) suggested that BPV E5 could play a role in inducing both fibroblastic and epithelial proliferation during natural infection, but no mechanism was proposed.
We have recently shown unequivocal expression of BPV-2 E5 in bovine bladder cancer, consistent with a causative role of BPV-2 and its oncoprotein E5 in carcinogenesis (Borzacchiello et al., 2003c) . The derived amino-acid sequence of BPV-2 E5 is identical to that of BPV-1 (http://hpv-web.lanl.gov/). In the present study, we show that the interaction between the E5 oncoprotein and the activated PDGF b receptor takes place in naturally occurring urinary bladder tumours in cattle.
Results

Histological types of tumour samples
In all, 35 urothelial cancer samples were investigated. Histologically, the tumour samples were diagnosed as follows: four dysplasias of various degrees; three carcinomas in situ (one of these was associated with a haemangiosarcoma); 13 noninfiltrating urothelial carcinomas (three of these were associated with haemangiomas and one was associated with a haemangiosarcoma); nine infiltrating urothelial carcinomas; four papillary urothelial carcinomas; two adenocarcinomas. Only the epithelial tumours were analysed in this study.
BPV-2 DNA in urinary bladder
The presence of BPV-2 in bladder cancers was ascertained by PCR, using a set of primers known to amplify a 311 bp fragment covering almost all the E5 coding sequence and part of the E2 open reading frame (Borzacchiello et al., , 2003c . A fragment of the expected size was amplified in 20 out of 35 tumour samples, from which DNA of PCR quality was obtained (Table 1) . Lower positivity (three out of 10) for BPV-2 sequences was detected in control bladder mucosa from healthy cows (Table 1) . To determine the papillomavirus type, the PCR amplicons were sequenced and proven to correspond to the expected region of BPV-2. No association was found between the presence of viral DNA and a particular type of tumour (data not shown). The amount of viral DNA in control bladder mucosa was less than in bladder cancers, as judged by the intensity of the PCR amplicons (Table 1; Borzacchiello et al., 2003c) , suggesting amplification of the viral genome during carcinogenesis.
PDGF b receptor expression in bovine bladder tissues Three samples of BPV-2-positive tumours of different epithelial histotype and one normal urothelial mucosa positive for BPV-2 DNA (but not E5 protein; Borzacchiello et al., 2003c) were analysed biochemically for expression and status of PDGF b receptor. The tumour samples were T4, carcinoma in situ, T15, papillary carcinoma and T20, adenocarcinoma. PDGF b receptor was detected both in the normal urothelium sample N2 and in the tumour samples by immunoprecipitation with an anti-PDGF b receptor antibody (PDGF b R #1; gift of Professor DiMaio), followed by Western blotting with a polyclonal antibody raised against amino acids 1013-1025 of human PDGF b receptor (PDGF b R #2; Upstate Biotechnology, Lake Placid, NY, USA). In all samples, the antibody recognized a band of the right molecular weight of similar intensities in both normal and neoplastic tissue (Figure 1) . No noticeable difference in PDGFb receptor expression levels between normal and neoplastic tissues was revealed by densitometric analysis (data not shown), indicating that the receptor is not overexpressed in cancer cells. Similar results were obtained in reciprocal experiments in which the immunoprecipitation and the Western blotting antibody were reversed (data not shown).
Detection of PDGF b receptor in normal bladder mucosa and bladder tumours The anti-PDGF b receptor polyclonal antibody #1 or monoclonal antibody #3 were used to stain histological sections of 20 BPV-2-positive tumour samples and six normal bladder mucosa (three positive for BPV-2 DNA but not for E5 protein, and three negative for BPV-2 DNA) ( Table 1) .
With either antibody and by either immunofluorescence or immunohistochemistry, PDGF b receptor was detected in all the epithelial layers and in the underlying mesenchyme and blood vessels of all normal mucosae, whether BPV-2 positive or negative (Figure 2a-c) . There was no observable difference in either the pattern or the intensity of staining for PDGF b receptor between BPV-2 DNA-positive and BPV-2 DNA-negative normal mucosa, thus suggesting that PDGF b receptor is expressed constitutively in the bladder epithelium independently of the presence of BPV-2 DNA. Similarly, PDGF b receptor was detected in the neoplastic epithelium and in the mesenchyme (see below and Figure 2d -l). Although immunofluorescence is not strictly quantitative, no obvious differences in signal intensity were observed between normal and neoplastic tissue, as already observed biochemically (Figure 1 ). The localization of PDGF b receptor in both the epithelium and mesenchyme of bovine urinary bladder was confirmed in tumours by confocal double-labelling immunofluorescence with two epithelial markers, cytokeratins and uroplakin III, and one mesenchymal marker, vimentin. The antibodies for these tissue markers recognized the respective antigens in Western blots of protein lysates from bladder tumours (data not shown). Uroplakin III is a highly specific marker for urothelial tumours, including human, canine and bovine tumours (Kaufmann et al., 2000; Ambrosio et al., 2001; Ramos-Vara et al., 2003; Roperto et al., 2005) . The expression of PDGF b receptor in the urothelium was confirmed by its coexpression with cytokeratins ( Figure  2d -f) and with the few cells expressing uroplakin III (Figure 2g-i) . As reported (Roperto et al., 2005) , uroplakin III is expressed only in the urothelial neoplastic cells in a discontinuous pattern, associated with luminal membranes, that is, the 'superficial pattern' (Roperto et al., 2005) . Similarly, the expression of PDGF b receptor in the mesenchyme was confirmed by The scoring of the levels of BPV-2 DNA was determined visually in PCR experiments (Borzacchiello et al., 2003c) . All samples were stained with anti-PDGF b receptor #1, antiphosphorylated PDGF b receptor and antiphosphotyrosine antibodies. The scoring of the antiphosphotyrosine immunoreactivity was determined in a 'blind' study by two observers (GB and VR). The intensity of the viral DNA PCR amplicons and of immunolabelling for each specimen was scored on a four-tiered scale of 0 to +++ as follows: 0, absent or very weak signal; +, weak signal; ++, moderate signal; +++, strong signal. E5 was detected by immunofluorescence as described (Borzacchiello et al., 2003c) and scored as positive (yes) or negative (no). Colocalization of E5 and PDGF b receptor was determined by double immunofluorescence and scored as yes. E5-PDGF b receptor interaction was determined for three epithelial tumours of different type and scored as yes (underlined) . N, clinically normal mucosa; T, tumour. NA, not applicable; ND, not determined. The underlined samples were analysed biochemically.
Figure 1
The PDGF b receptor is not overexpressed in BPV-2-positive tumour samples. PDGF b receptor was immunoprecipitated from cellular lysates of three tumours of different histological type (T4, T15, T20; see Table 1 ) with the PDGF b receptor antibody #1. The precipitates were probed with the anti-human PDGF b receptor antibody #2. The arrow on the right indicates the PDGF b receptor. Essentially identical results were obtained when the order of antibodies was inverted. T4, T15, T20: BPV-2-positive tumour samples, N2, normal bladder sample. In a parallel blot, the same amount of lysate was probed with an antibody to b-actin to control for the quantity of protein (bottom panel).
its colocalization with vimentin ( Figure 2j -l). Although no previous information on the expression of PDGF b receptor in bovine epithelia is available, PDGF b receptor has been found in cervical, ovarian and breast epithelia, among others, and in the corresponding cancers (Coltrera et al., 1995; Mayer et al., 2000; Schmandt et al., 2003) , similar to our findings. Out of 20 neoplastic samples, 18 (90%) were positive for PDGF b receptor, T6 and T11 being the only two tumours which did not show a positive staining (Table 1; T11 shown in Figure 2s -u). The immunolabelling ranged from faint to strong; the score for the different samples is reported in Table 1 . Despite its presence in both urothelium and mesenchyme of normal and neoplastic bladder mucosa, the receptor was phosphorylated (activated) only in neoplastic urothelium (see below and Figure 5 ).
Colocalization of E5 and PDGF b receptor in bladder tumours
As the PDGF b receptor was present in the epithelium and was intracytoplasmic and occasionally clearly membrane-associated (Figure 2i ), we wondered whether it may be associated with E5, as has been reported in cultured cells (Petti and DiMaio, 1992) .
To investigate a possible colocalization of PDGF b receptor and E5, an anti-E5 antibody (gift from Professor Schlegel) was used in addition to the anti-PDGF b receptor monoclonal antibody #3 in a doublecolour immunofluorescence assay (green fluorescence for E5 and red fluorescence for PDGF b receptor). Six of the 18 tumours positive for PDGF b receptor (T4, T7, T8, T15, T17, T20) and the three BPV-2 DNA-positive control mucosa samples (N1-N3) were used. E5 protein was detected in tumours, in both dysplastic and neoplastic urothelium (Figure 2n Table 1 ). Most cells in the neoplastic urothelium showed cytoplasmic colocalization of E5 and PDGF b receptor, as judged by the yellow fluorescence of the merged images (Figure 2m-o) . Interestingly, both proteins appeared to localize often in a juxtanuclear position (arrows in Figure 2o ). Normal urothelium showed, as expected, no E5 signal (data not shown). All the tumours analysed showed similar staining patterns and colocalization of E5 and PDGF b receptor, independently of their histotype. Similar results were obtained with anti-PDGF b receptor antibodies #1 and #2 (data not shown).
Physical interaction between E5 and PDGF b receptor
To determine whether the PDGF b receptor was in a molecular complex with the E5 protein, the ability of E5 to co-precipitate with the PDGF b receptor was assessed in the three tumours (T4, T15, T20) analysed in Figure 1 (out of the six tumours in which E5 and PDGF b receptor colocalized by immunofluorescence; Table 1 (Figure 3a) showed that approximately 80% of the receptor is in a molecular complex with E5 in cancer specimens (data not shown), indicating that the majority of the receptor is in complex with E5.
PDGF b receptor is hyperphosphorylated in cancers and is complexed with E5 To determine the phosphorylation status of the PDGF b receptor in the bladder cancers, the immunoprecipitates obtained from tumours T4, T15, T20 and normal mucosa N2 with the anti-PDGF b receptor antibody #1 (Figure 3b) were analysed in Western blotting with an antiphosphotyrosine (APT) antibody. A strong single band was observed corresponding to the expected molecular size (Figure 4a ). The identity of the band as PDGF b receptor was confirmed by stripping the membrane and reprobing it with the antibody against PDGF b receptor #2. There was a substantial increase in phosphorylated PDGF b receptor in bladder cancer versus normal mucosa, demonstrating that the receptor is activated in the cancers more than in normal tissue. To determine the phosphorylation status of the PDGF b receptor in complex with E5, the E5 immunoprecipitates ( Figure 3a) were probed by Western blotting with the APT antibody. A single strong band of the expected molecular size, corresponding to the PDGF b receptor, was obtained (Figure 4b) , showing that the receptor in complex with E5 is phosphorylated. Please note that the PDGF b receptor panel in Figure 4b is the same as that of Figure 3a .
Receptor phosphorylation was confirmed in tumours by immunohistochemistry with antibodies against phosphotyrosine and against PDGF b receptor phosphorylated at tyrosine 1021. With either antibody, while immunostaining was barely detected in the upper layers of the urothelium and in the mesenchyme of both BPV-2 DNA-positive and -negative normal mucosa (Figure 5c e), in tumour samples the intensity of phosphorylated receptor or phosphotyrosine staining was very high in the epithelium, but not in the mesenchyme (Figure 5a, b ; Table 1 ). In addition, phosphorylated receptor colocalized with E5-expressing cells (Figure 5f-h) .
Out of 20 cancer samples which showed strong PDGF b receptor expression, 10 (50%) also exhibited strong phospho-immunostaining, five (25%) showed moderate staining, and the remainder, weak or no staining. In contrast, the normal mucosal samples showed weak or no staining, independently of their BPV-2 status (Table 1 ).
Discussion
We have already shown a strong association between BPV-2 and cancer of the urinary bladder in cattle, both in naturally occurring tumours and in experimental conditions (Campo et al., 1992; Borzacchiello et al., 2003c) . We have also shown that, although BPV-2 DNA can be found in normal urothelium, the viral E5 oncoprotein is expressed only in the cancers (Borzacchiello et al., 2003c), suggesting a causal role in the neoplastic process. We now present data that strongly support a major role of E5 in carcinogenesis of the urinary bladder by showing that E5 and phosphorylated (activated) PDGF b receptor form a stable complex in the cancer cells.
Several lines of evidence support this conclusion. First, E5 and PDGF b receptor colocalize, occasionally in a juxtanuclear position, consonant with the location of E5 in the GA (Burkhardt et al., 1989; Pennie et al., 1993) . Second, E5 and PDGF b receptor co-precipitate, whether anti-E5 or anti-PDGF b receptor antibody is used. Third, PDGF b receptor is more highly phosphorylated in cancer cells than in nontransformed tissue, and, fourth, the hyperphosphorylated receptor colocalizes with E5 and is in complex with E5. The above observations have been made in epithelial tumours of diverse type, thus ruling out tumour-type-dependent effects.
BPV E5 induces oncogenic cell transformation in cultured rodent fibroblasts and keratinocytes (Leptak et al., 1991; Petti et al., 1991) . In cultured fibroblasts, E5 binds to and activates the PDGF b receptor (Petti et al., 1991; DiMaio et al., 2000) , whereas it does not directly activate either the PDGF a receptor or the EGF receptor (Petti and DiMaio, 1994) . E5 induces receptor activation by forming a stable complex with the receptor, thereby inducing its dimerization and transphosphorylation of tyrosine residues in the cytoplasmic domain of the receptor itself . These results were obtained in cultured transformed fibroblasts, and it was only hypothesized that the E5 protein may interact with cellular targets other than PDGF receptor (e.g. EGF receptor) in epithelial cells (Leptak et al., 1991) .
PDGF b receptor is commonly expressed in the mesenchyme and no previous information was available on the expression of the receptor in bovine epithelia. Our results show that the PDGF b receptor is expressed not only in the mesenchyme but also in the urothelium of both normal and neoplastic bovine bladder. The simultaneous presence of PDGF b receptor and uroplakin III in the urothelium is definite proof that PDGF b receptor is expressed in epithelial cells: uroplakin expression is urothelium-specific (Sun et al., 1999) and is a highly sensitive and specific marker for urothelial tumours, including bovine urothelial neoplasias (Roperto et al., 2005) . These observations are in agreement with previous reports that the receptor is expressed in cervical, ovarian and breast epithelia, among others, and in the corresponding cancers (Coltrera et al., 1995; Mayer et al., 2000; Schmandt et al., 2003) .
In the neoplastic epithelial cells of bladder cancer, the PDGF b receptor, although not overexpressed, is activated, as judged by the degree of its phosphorylation. It is worth noting that the presence of 'latent' (nonexpressed) BPV-2 DNA in normal bladder urothelium does not affect the expression or the phosphorylation status of the PDGF b receptor. As the activated receptor is complexed with E5 and perfectly colocalizes with the oncoprotein, we suggest that the physical interaction with E5 induces receptor dimerization and trans-phosphorylation in vivo, as already demonstrated in vitro (Lai et al., 1998 .
It is also possible that the higher phosphorylation of PDGF b receptor observed in bovine bladder cancers is due to impaired processing and recycling of the receptor in the endomembrane compartments. E5 proteins bind to the 16 kDa transmembrane subunit c of the vacuolar H þ -ATPase Conrad et al., 1993; Faccini et al., 1996) and this interaction is considered responsible for the increase in pH of the GA and endosomes (Straight et al., 1995; Schapiro et al., 2000) and their altered morphology (Ashrafi et al., 2000) . The alkalinization of the endomembranes could lead to changes in receptor trafficking/processing, and disruption of exocytic and endocytic cellular traffic. This is indeed the case in BPV E5 transformed bovine cells and in human keratinocytes expressing HPV E5. In the former, impeded acidification of the GA leads to inhibition of the export of MHC class I complex to the cell surface Marchetti et al., 2002) . In the latter, endosomal pH changes are associated with higher levels of ligand-induced phosphorylation of EGF receptors (Straight et al., 1993) .
The great majority of the studies on the functions of E5 have been conducted in vitro. Only recently indications of the role of E5 in the establishment of papillomavirus infection and cell transformation have been obtained. A possible function of E5 in vivo is the downregulation of the MHC class I complex in BPV-4-induced papillomas, likely to affect host immune surveillance and clearance of virally infected cells (Araibi et al., 2004) . The interaction between E5 and hyperphosphorylated PDGF b receptor, described here, is likely to be a main contributor to naturally occurring BPV-induced epithelial cancers.
It has recently been suggested that the investigation of animal papillomaviruses is still valuable for the study of HPV infection, as well as for the development of antiviral vaccines (Campo, 2002) . Our investigation into the functions of BPV E5 in naturally occurring bladder cancers contributes to the understanding of papillomavirus-induced carcinogenesis. HPV E5 proteins may represent a target for therapeutic intervention. Recently, it has been shown that vaccination of mice with HPV-16 E5 can elicit cytotoxic T lymphocytes, which inhibit the growth of murine tumour cells (Liu et al., 2000; Chen et al., 2004) . Successful E5 vaccination of affected cattle would provide an ideal model for the development of therapeutic vaccines for comparable human pathologies.
Materials and methods
Animals and tumour samples
Samples of neoplastic urothelium were collected at public slaughterhouses from 4-to 24-year-old cows that had been suffering from CEH for several years. All the animals were raised in mountain cattle households in Southern Italy and known to graze on bracken-infested pasturelands (Borzacchiello et al., 2003a) .
Histological diagnosis was assessed on 4-mm-thick haematoxylin-eosin-stained sections. In all, 35 cancer samples were analysed. Histologically the tumour samples were diagnosed as follows: four dysplasias of various degrees; three carcinomas in situ (one of these was associated with a haemangiosarcoma); 13 noninfiltrating urothelial carcinomas (three of these were associated to haemangiomas and one was associated with a haemangiosarcoma); nine infiltrating urothelial carcinomas; four papillary urothelial carcinomas; two adenocarcinomas. Half of each neoplastic bladder sample was immediately frozen at -801C for viral and molecular analysis. Associated haemangiomas and haemangiosarcomas were not investigated. Normal urothelium, from 4-to 24-year-old healthy cows, was also examined as control.
Detection of viral DNA For viral DNA analysis, a small fragment of frozen tissue from 35 urothelial tumours and 10 normal urothelial mucosa was digested by Proteinase-K in lysis buffer (50 mM KCl, 10 mM Tris HCl, pH 8.3, 2.5 mM MgCl 2 , 100 mg/ml gelatin, 0.45% NP-40 and 0.45% Tween-20) to recover DNA. PCR amplification of viral sequences using consensus primers was carried out according to methods described previously . The primer set consisted of a forward primer (5 0 -TTGCTGCAATGCAACTGCTG-3 0 , nt 3919-3938) and a reverse primer (5 0 -TCATAGGCACTGGCACGTT-3 0 , nt 4207-4225). The primers amplify a fragment of 311 bp encompassing almost all the BPV E5 sequence part of the E2 open reading frame . The primers were added at 0.4 mM final concentration to a Perkin-Elmer GeneAmp kit. The thermal cycling was carried out at 941C for 2 min, 551C for 2 min and 741C for 1 min, for 30 cycles. A fragment corresponding to the expected size was amplified in 20 of 35 samples, from which DNA of PCR quality was obtained. To determine the papillomavirus type, PCR amplicons were sequenced and proven to correspond to the expected region of BPV-2.
In each experiment, a blank sample consisting of reaction mixture without DNA and a positive sample consisting of BPV-2-cloned DNA were included.
Antibodies
Antibodies used were: a rabbit anti-E5 antibody (kindly provided by Professor R Schlegel, Georgetown University, USA); a rabbit polyclonal antibody against the C-terminus of PDGF b receptor (#1; kindly provided by Professor D DiMaio, Yale University, USA); a rabbit polyclonal antibody raised against aa 1013-1025 of human PDGF b receptor containing a carboxy-terminal alanine residue (#2; Upstate Biotechnology, Lake Placid, NY, USA); a mouse monoclonal antibody raised against the highly conserved aa 1-187 of human PDGF b receptor with broad-range reactivity against other mammalian species (#3; BD Transduction, San Jose, CA, USA); a goat polyclonal antibody raised against PDGF b receptor phosphorylated at tyrosine 1021 (sc-12909, Santa Cruz Biotechnology, Inc.); a mouse APT monoclonal antibody (Clone 4G10; Upstate Biotechnology, Lake Placid, NY, USA); a rabbit polyclonal anti-cytokeratin antibody raised against bovine cytokeratins (DakoCytomation, Denmark); a rabbit polyclonal anti-uroplakin III antibody raised against highly purified bovine uroplakin III (kindly provided by Professor Tung Tien Sung, New York University School of Medicine, New York, NY, USA); a rabbit polyclonal anti-vimentin antibody (Abcam, Cambridge, UK) and a goat polyclonal anti-vimentin antibody (Sigma, Milan, Italy) . The rabbit and goat anti-vimentin antibodies were used in two-colour immunofluorescence with the mouse monoclonal antibody against PDGF b receptor and the rabbit polyclonal antibody against E5, respectively.
Immunohistochemistry
Twenty BPV-2-positive dysplastic and neoplastic samples, three BPV-2 DNA-positive and three BPV-2 DNA-negative normal bladder mucosa samples were stained (Table 1) . Briefly, paraffin sections were deparaffinized, and blocked for endogenous peroxidase in 0.3% H 2 O 2 in methanol for 20 min. Antigen enhancement was performed by pretreating with microwave heating (twice for 5 min each at 750 W). The primary antibodies were applied overnight at room temperature in a humified chamber. The anti-PDGFb receptor #1 was applied at 1:1000 dilution; the anti-PDGF b receptor phosphorylated at tyrosine 1021 was applied at 1:2000 dilution; the APT antibody was applied at 1:500 dilution.
The slides were washed three times with phosphate-buffered saline (PBS), then incubated for 30 min with the appropriate biotinylated secondary antibody (labelled streptavidin-biotin (LSAB) Kit; DakoCytomation, Denmark). Sections were washed three times with PBS and then incubated with streptavidin-conjugated to horseradish peroxidase (LSAB Kit; DakoCytomation, Denmark). Colour development was obtained by treatment with diaminobenzidine (DakoCytomation, Denmark) for 5-20 min. Sections were counterstained with Mayer's haematoxylin. In the corresponding negative control section, the primary antibodies were either omitted or replaced with appropriate normal sera.
The scoring of the immunoreactivity was determined in a 'blind' study by two observers (GB and VR). The intensity of labelling in each specimen was scored on a four-tiered scale of 0 to þ þ þ (Table 1) as follows: 0, absent or very weak immunosignal; þ , weak immunosignal; þ þ , moderate immunosignal; þ þ þ , strong immunosignal.
Immunofluorescence and confocal laser-scanning microscopy For two-colour immunofluorescence staining of PDGF b receptor with cytokeratins, uroplakin III or vimentin, PDGF b receptor was detected with mouse monoclonal antibody #3 at 1:100 dilution applied overnight at room temperature in a humidified chamber and a tetramethylrhodamine isothiocyanate (TRITC)-conjugated donkey anti-mouse secondary IgG antibody at 1:30 dilution (Jackson ImmunoResearch Laboratories Inc., West Grove, OK, USA); the polyclonal anticytokeratin antibody was used at 1:200 dilution; the polyclonal anti-uroplakin III antibody was used at 1:50 dilution, and the polyclonal anti-vimentin antibody was used at 1:100 dilution. All the antibodies were applied overnight at room temperature in a humidified chamber and detected with a fluorescein isothiocyanate (FITC)-conjugated donkey anti-rabbit secondary IgG antibody diluted 1:30 (Jackson ImmunoResearch Laboratories Inc., West Grove, OK, USA). After washing three times with PBS, the slides were mounted in aqueous medium (Sigma, Milan, Italy) .
For colocalization analysis of PDGF b receptor and E5, the antiphosphorylated PDGF b receptor monoclonal antibody #3 was used and detected by TRITC-conjugated donkey antimouse IgG as above; anti-E5 antibody was applied overnight at room temperature at 1:50 dilution in a humidified chamber and detected with a FITC-conjugated donkey anti-rabbit IgG as above. After a final washing, the slides were mounted in aqueous medium as above.
For colocalization analysis of phosphorylated PDGF b receptor and E5, the anti-PDGF b receptor antibody was incubated overnight at room temperature at 1:200 dilution and detected by TRITC-conjugated donkey anti-goat IgG (Jackson ImmunoResearch Laboratories Inc., West Grove, OK, USA) as above; anti-E5 antibody was applied overnight at room temperature at 1:50 dilution and detected with an FITCconjugated donkey anti-rabbit IgG as above. After a final washing, the slides were mounted in aqueous medium as above.
For two-colour immunofluorescence staining of E5 and vimentin, the anti-E5 antibody was used as above and the goat polyclonal anti-vimentin antibody was used at 1:200 dilution; the primary antibodies were detected by TRITC-conjugated donkey anti-goat (vimentin) and FITC-conjugated donkey anti-rabbit (E5) IgG secondary antibodies diluted 1:30. The slides were processed as above.
For scanning and photography, a confocal laser-scanning microscope LSM-510 (Zeiss, Go¨ttingen, Germany) was used. FITC was irradiated at 488 nm and detected via a 505-560 nm band pass filter. TRITC was irradiated at 543 nm and detected with a 560 nm band pass filter. Two-channel frame-by-frame multitracking was used for detection to avoid 'cross-talk' signals. The different frames were scanned separately, with appropriate installation of the optical path for excitation and emission of each scan according to the manufacturer's instructions.
Protein extraction and coimmunoprecipitation
Three samples of BPV-2-positive neoplastic tissues and one normal urothelial mucosa positive for BPV-2 DNA (but not E5 protein; Borzacchiello et al., 2003c) were frozen in liquid nitrogen and homogenized in JS buffer (1 M Hepes, pH 7.5, 5 M NaCl, glycerol, 10% Triton X-100, 1 M MgCl 2 , 0.1 M EGTA, 0.1 M sodium pyrophosphate, aprotinin, 0.1 M phenylmethylsulfonyl fluoride (PMSF), 500 mM sodium orthovanadate (Na 2 VO 3 ), 2 M NaF) or in RIPA buffer (20 mM Mops, 150 mM NaCl, 1% Nonidet P-40, 0.1 M EDTA, 1% sodium deoxycholate, 1 M PMSF, 500 mM Na 2 VO 3 , 0.1% SDS). The quantity of proteins was determined by use of a protein assay kit (Biorad -Protein Assay). A-Sepharose beads (Pharmacia) (0.08 g/ml) were swollen for 1 h in TBS (10 mM Tris-HCl, pH 7.4, 165 mM NaCl). In all, 0.5 ml of A-Sepharose beads was added to 0.5 ml of the homogenate and the mixture was rotated overnight at 41C for pre-clearing. Also, 2.5 ml of the appropriate antibody (anti-PDGF b receptor or anti-E5) was added to 0.5 ml of A-Sepharose beads and the mixture was rotated overnight at 41C. The beads were washed five times with TBS or RIPA buffer and were added to 0.5 ml of the precleared homogenized. The mixture homogenized was rotated overnight at 41C for immunoprecipitation. The beads were washed five times with TBS or RIPA buffer and then resuspended in Laemmli sample buffer (SDS, Tris-HCl, pH 6.8, glycerol, bromophenol blue, b-mercaptoethanol) and boiled for 5 min. The beads were pelleted and the supernatant was decanted in a new tube.
SDS PAGE/Western blotting
The immunoprecipitates were loaded on 6% bis/acrylamide gel and electrophoresed. The proteins were blotted from the gel onto nitrocellulose membranes. The membranes were blocked with 5% non-fat dry milk in TBS buffer at room temperature, washed with TBS-0.1% Tween and incubated with antibodies against PDGF b receptor, E5 or phosphotyrosine (clone 4G10; Upstate Biotechnology, Lake Placid, NY, USA).
An mAb AB-1 (Calbiochem) specific for actin was also used to control for the quantity of the protein in the analysed samples.
Densitometric analyses of Western blotting were performed on a Macintosh computer using the public domain NIH Image program (developed at the US National Institutes of Health and available on the Internet at http://rsb.info.nih.gov/ nih-image/).
